ISCO Collaborates with Florey Institute of Neuroscience and Mental Health for Clinical Research

By CIOReview | Thursday, December 31, 2015
716
1203
278

FREMONT, CA: A new pledge has been announced in biotechnology industry: International Stem Cell Corporation, a biotechnology company, has entered into a clinical research agreement with the Florey Institute of Neuroscience and Mental Health to conduct a Phase I/IIa clinical trial, dose escalation trails of human parthenogenetic stem cells - derived neural stem cells (ISC-hpNSC) that are intracranialy transplanted into in Parkinson’s disease patients. 

Parkinson’s disease is a degenerative disorder of the central nervous system marked by tremor, muscular rigidity and slow, imprecise movement that mainly affect middle-aged and elderly people. As the disease progresses over time, symptoms related to Parkinson's disease typically get worse that impact on the quality of life of sufferers and heads a number of clinical research trials.

Parkinson's disease is the second most common neurodegenerative disease which has no cure and is affecting millions of people worldwide. International Stem Cell Corporation reckons ISC-hpNSC may have broad therapeutic applications for parkinson’s disease and many other neurological diseases affecting the brain, the spinal cord and the eye.

"We recently received authorization to initiate Phase I/IIa and now we are moving forward towards formal engagement of the clinical site to conduct this study. We are excited to work together with the Florey to conduct the clinical trials of ISC-hpNSC at the Royal Melbourne Hospital," said Russell Kern, PhD, Executive Vice President, Chief Scientific Officer, International Stem Cell Corporation. 

Kern commented that ISCO is the first company in the world to conduct clinical trials of human pluripotent stem cells based product for the treatment of Parkinson's disease. The company believes that the outcome of the study will produce findings in-line with our preclinical studies, where they can demonstrate not only safety of their proprietary neural stem cells, but also their functional efficacy. The cells were able to successfully integrate into the brain and provide a significant increase of dopamine levels in the nigrostriatal system, Kern adds.